Hugh Grant has a famous rant about the unbearability of slow walkers. From road-raging speed demons to travelers rushing to board airplanes, most of us recognize the simmering irritation that comes from being slowed down by someone else. Impatience is still a socially acceptable emotion and we laugh at Hugh Grant’s outrage because we get…
Month: December 2025
Natalizumab under the skin is liked over infusion
Tweet Natalizumab is typically given as 300mg intravenous infusion every month, as the patent life of natalizumab expired a new route was developed and that is subcutaneous or under the skin. It is whacked in a lot quicker and may be delivered at home. This saves the UK PLC money as home delivery does not…
Strength & Determination
It has been a little while since I posted. Honestly, the only reason I haven’t posted is that I have been reading and trying my best to avoid Christmas. I am unsure why, but I found it nearly impossible to get in the holiday spirit this year. Regardless of my feelings about Christmas, I hope you and your family…
Top 10 MS news stories of 2025
Throughout 2025, the team at Multiple Sclerosis News Today brought our readers the latest advances and updates in research related to multiple sclerosis (MS). Below are the top 10 most-read news stories we published this year. We look forward to continuing to serve the MS community in 2026 and the years beyond. No. 10 –…
Are Neuros really that gullible?
Tweet A few years ago we had the comment was will the real MS stand up and the suggestion that there were distinct processes where the immune system enters the CNS to drive the damage and the other process that the damage is caused by immune responses in the CNS calling in the immune system….
Ask the Expert: Depression
Featuring Barry A. Hendin, MD MSAA’s Chief Medical Officer Barry Hendin, MD Question: What should care partners do if they suspect depression in their loved one with MS, and what are the treatment options? Answer: Like other medical illnesses, depression … Continue reading → Source: blog.mymsaa.org
FDA denies tolebrutinib approval for nonrelapsing progressive MS
After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again and that further guidance from the FDA was expected…
The 72 hours I borrow my body back
The hardest part of my Multiple Sclerosis Rituxan infusion isn’t the struggle to find a plump vein for an IV placement, or the five hours Dan and I spend in the infusion center, or even the fatigue that follows. The hardest part is the dose of Solu-Medrol that the nurses give me before my treatment…
Anti-Lingo Trial
Tweet This work was done and completed years ago and the take home message is that the results weren’t good enough of it to be developed. Lingo-1 is part of the pathway that prevents nerve regeneration , but it was also reported to inhibit remyelination. In early trials that was dose ranging dosing up to…
Emergency-Paging Dr.K
Tweet OK its not Dr Beat its ProfK. They “argue that despite significant advances in MS immunotherapy, and framework ideas to prevent the disease altogether, MS clinicians, let alone the general neurology community, regularly fails to make effective use of secondary preventive strategies. Clinical practice remains conservative. Many patients start treatment months—or even years—after diagnosis,…